))
Healthcare Systems Readiness: What is Limiting the RLT Scale-up?
Manage episode 436733472 series 3585940
Content provided by JNM. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by JNM or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
Radioligand therapy (RLT) targets cancer cells with radiation while minimizing impact on surrounding healthy tissue. In this episode of JNM Podcast, our panelists discuss training, access, production capacity, and everything else that is necessary to make RLT more widely available to the patients who need it.
Moderator: Ken Herrmann, MD (Universitätsmedizin, Essen, Germany).
Panelists: Andrei Iagaru, MD (Stanford University Medical Center, Stanford, California), Leonhard Schaetz (Novartis, Basel, Switzerland), and Désirée Deandreis, MD (Gustave Roussy, Villejuif, France).
Sponsored by SOFIE Biosciences (https://sofie.com)
6 episoade
Distribuie
